Brain Radiation Protection: New Approach Prevents Cognitive Decline
- Researchers at the University of California, Irvine, have identified a potential method to mitigate cognitive decline caused by cranial radiation therapy for brain cancer, offering hope for improved...
- While overcoming cancer is a significant achievement, many survivors face lasting challenges, including cognitive impairments.
- Cranial radiation therapy, a common treatment for brain cancers, is a known contributor to CRCI.The radiation, while targeting cancerous cells, also damages healthy brain tissue, triggering neuroinflammation and...
“`html
UC Irvine Study Shows Promise in Protecting Brains from cancer Treatment Side Effects
Table of Contents
Researchers at the University of California, Irvine, have identified a potential method to mitigate cognitive decline caused by cranial radiation therapy for brain cancer, offering hope for improved quality of life for survivors.
While overcoming cancer is a significant achievement, many survivors face lasting challenges, including cognitive impairments. These impairments, known as cancer-related cognitive impairment (CRCI), effect up to 70% of survivors, causing difficulties with memory and concentration, and ultimately diminishing their quality of life and independence National Cancer Institute: Cancer-Related Cognitive Impairment.
Cranial radiation therapy, a common treatment for brain cancers, is a known contributor to CRCI.The radiation, while targeting cancerous cells, also damages healthy brain tissue, triggering neuroinflammation and leading to cognitive decline. Currently, there are limited effective strategies to prevent or reverse these effects.
UC Irvine Researchers Identify a Potential Solution
A new study led by Munjal acharya,PhD,associate professor in the Department of Anatomy & Neurobiology at UC Irvine,offers a promising avenue for protecting the brain from radiation-induced cognitive decline. The research,published in “C5aR1 Inhibition Alleviates Cranial Radiation-Induced Cognitive Decline” in Cancer Research on , details a targeted approach to mitigate these harmful effects.
“We’ve identified a new,targeted way to protect the brain from the harmful side effects of cranial radiation therapy,a standard of care for brain cancers that often causes irreversible cognitive decline,” stated Acharya. ”this opens a realistic pathway to preserving quality of life for millions of brain cancer survivors currently facing this unmet medical need.”
Targeting the Complement Cascade
The researchers discovered that inhibiting a specific immune response pathway in the brain – the complement cascade – can protect memory and cognition from the neuro-inflammatory effects of radiation therapy. The complement cascade is a crucial part of the innate immune system, but its overactivation can contribute to inflammation and tissue damage.
Specifically, the study focused on blocking the C5aR1 receptor, a key component of the complement cascade. By inhibiting C5aR1,the researchers were able to considerably reduce neuroinflammation and preserve cognitive function in animal models treated with cranial radiation. This suggests that targeting this pathway could offer a therapeutic strategy for preventing CRCI in human patients.
The study utilized a novel small-molecule inhibitor of C5aR1. This inhibitor was administered to mice before and during cranial radiation therapy. The results demonstrated that the treated mice exhibited significantly improved performance on cognitive tests compared to control mice.
Implications and Future Directions
These findings represent a significant step forward in addressing the often-overlooked issue of CRCI. While further research is needed, the study provides